Trial Profile
A Phase IV, Multicenter, Single-Arm, Open-Label Study to Assess the Efficacy and Safety of Tocilizumab in Chinese Patients With Systemic Juvenile Idiopathic Arthritis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Nov 2022
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary)
- Indications Juvenile rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Roche
- 11 Nov 2022 Status changed from active, no longer recruiting to completed.
- 14 Apr 2022 Planned End Date changed from 26 Apr 2022 to 24 Nov 2022.
- 27 Jul 2021 Status changed from recruiting to active, no longer recruiting.